Your browser doesn't support javascript.
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Sanchez-Felipe, Lorena; Vercruysse, Thomas; Sharma, Sapna; Ma, Ji; Lemmens, Viktor; Van Looveren, Dominique; Arkalagud Javarappa, Mahadesh Prasad; Boudewijns, Robbert; Malengier-Devlies, Bert; Liesenborghs, Laurens; Kaptein, Suzanne J F; De Keyzer, Carolien; Bervoets, Lindsey; Debaveye, Sarah; Rasulova, Madina; Seldeslachts, Laura; Li, Li-Hsin; Jansen, Sander; Yakass, Michael Bright; Verstrepen, Babs E; Böszörményi, Kinga P; Kiemenyi-Kayere, Gwendoline; van Driel, Nikki; Quaye, Osbourne; Zhang, Xin; Ter Horst, Sebastiaan; Mishra, Niraj; Deboutte, Ward; Matthijnssens, Jelle; Coelmont, Lotte; Vandermeulen, Corinne; Heylen, Elisabeth; Vergote, Valentijn; Schols, Dominique; Wang, Zhongde; Bogers, Willy; Kuiken, Thijs; Verschoor, Ernst; Cawthorne, Christopher; Van Laere, Koen; Opdenakker, Ghislain; Vande Velde, Greetje; Weynand, Birgit; Teuwen, Dirk E; Matthys, Patrick; Neyts, Johan; Jan Thibaut, Hendrik; Dallmeier, Kai.
  • Sanchez-Felipe L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Vercruysse T; Global Virus Network (GVN), Baltimore, MD, USA.
  • Sharma S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Ma J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Lemmens V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Van Looveren D; Global Virus Network (GVN), Baltimore, MD, USA.
  • Arkalagud Javarappa MP; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Boudewijns R; Global Virus Network (GVN), Baltimore, MD, USA.
  • Malengier-Devlies B; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Liesenborghs L; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kaptein SJF; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • De Keyzer C; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Bervoets L; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Debaveye S; Global Virus Network (GVN), Baltimore, MD, USA.
  • Rasulova M; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Seldeslachts L; Global Virus Network (GVN), Baltimore, MD, USA.
  • Li LH; KU Leuven Department of Microbiology, Immunology and Transplantation,Rega Institute, Immunity and Inflammation Research Group, Immunobiology Unit, KU Leuven, Leuven, Belgium.
  • Jansen S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Yakass MB; Global Virus Network (GVN), Baltimore, MD, USA.
  • Verstrepen BE; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Böszörményi KP; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kiemenyi-Kayere G; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • van Driel N; Global Virus Network (GVN), Baltimore, MD, USA.
  • Quaye O; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Zhang X; Global Virus Network (GVN), Baltimore, MD, USA.
  • Ter Horst S; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Mishra N; Global Virus Network (GVN), Baltimore, MD, USA.
  • Deboutte W; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Matthijnssens J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), KU Leuven, Leuven, Belgium.
  • Coelmont L; KU Leuven Department of Imaging and Pathology, Biomedical MRI and MoSAIC, KU Leuven, Leuven, Belgium.
  • Vandermeulen C; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Heylen E; Global Virus Network (GVN), Baltimore, MD, USA.
  • Vergote V; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Schols D; Global Virus Network (GVN), Baltimore, MD, USA.
  • Wang Z; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Bogers W; Global Virus Network (GVN), Baltimore, MD, USA.
  • Kuiken T; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana.
  • Verschoor E; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Cawthorne C; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Van Laere K; Department of Virology, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Opdenakker G; Animal Science Department, Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands.
  • Vande Velde G; Global Virus Network (GVN), Baltimore, MD, USA.
  • Weynand B; West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Accra, Ghana.
  • Teuwen DE; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Matthys P; Global Virus Network (GVN), Baltimore, MD, USA.
  • Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
  • Jan Thibaut H; Global Virus Network (GVN), Baltimore, MD, USA.
  • Dallmeier K; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Virology and Chemotherapy, Molecular Vaccinology and Vaccine Discovery, KU Leuven, Leuven, Belgium.
Nature ; 590(7845): 320-325, 2021 02.
Article in English | MEDLINE | ID: covidwho-953381
Semantic information from SemMedBD (by NLM)
1. yellow fever vaccine PART_OF Mandibular left third molar distal hemisection
Subject
yellow fever vaccine
Predicate
PART_OF
Object
Mandibular left third molar distal hemisection
2. Antibodie PART_OF C5203676
Subject
Antibodie
Predicate
PART_OF
Object
C5203676
3. Hamsters LOCATION_OF Antibodie
Subject
Hamsters
Predicate
LOCATION_OF
Object
Antibodie
4. Macaca fascicularis LOCATION_OF Antibodie
Subject
Macaca fascicularis
Predicate
LOCATION_OF
Object
Antibodie
5. Mus LOCATION_OF Antibodie
Subject
Mus
Predicate
LOCATION_OF
Object
Antibodie
6. cell mediated immune response PROCESS_OF Mus
Subject
cell mediated immune response
Predicate
PROCESS_OF
Object
Mus
7. Lung diseases PROCESS_OF Animals
Subject
Lung diseases
Predicate
PROCESS_OF
Object
Animals
8. yellow fever vaccine PART_OF Mandibular left third molar distal hemisection
Subject
yellow fever vaccine
Predicate
PART_OF
Object
Mandibular left third molar distal hemisection
9. Antibodies, Neutralizing PART_OF 2019 novel coronavirus
Subject
Antibodies, Neutralizing
Predicate
PART_OF
Object
2019 novel coronavirus
10. Hamsters LOCATION_OF Antibodies, Neutralizing
Subject
Hamsters
Predicate
LOCATION_OF
Object
Antibodies, Neutralizing
11. Macaca fascicularis LOCATION_OF Antibodies, Neutralizing
Subject
Macaca fascicularis
Predicate
LOCATION_OF
Object
Antibodies, Neutralizing
12. Mus LOCATION_OF Antibodies, Neutralizing
Subject
Mus
Predicate
LOCATION_OF
Object
Antibodies, Neutralizing
13. cell mediated immune response PROCESS_OF Mus
Subject
cell mediated immune response
Predicate
PROCESS_OF
Object
Mus
14. Lung diseases PROCESS_OF Animals
Subject
Lung diseases
Predicate
PROCESS_OF
Object
Animals
ABSTRACT
The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efficacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1. Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efficacy in several animal models. YF-S0 has an excellent safety profile and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and-concomitantly-protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profiled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Attenuated / Yellow Fever Vaccine / COVID-19 Vaccines / Genetic Vectors / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-3035-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Attenuated / Yellow Fever Vaccine / COVID-19 Vaccines / Genetic Vectors / SARS-CoV-2 / COVID-19 Topics: Vaccines Limits: Animals Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-3035-9